Royce & Associates LP decreased its position in Bioventus Inc. (NASDAQ:BVS – Free Report) by 12.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,609,160 shares of the company’s stock after selling 224,052 shares during the period. Royce & Associates LP’s holdings in Bioventus were worth $21,933,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in BVS. Dimensional Fund Advisors LP raised its stake in shares of Bioventus by 14.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after buying an additional 107,930 shares during the last quarter. Engine Capital Management LP acquired a new stake in Bioventus in the 1st quarter valued at about $2,876,000. Lazard Asset Management LLC increased its holdings in Bioventus by 12.9% during the 1st quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock valued at $2,789,000 after acquiring an additional 35,008 shares in the last quarter. Sei Investments Co. increased its holdings in Bioventus by 160.7% during the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after acquiring an additional 178,539 shares in the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Bioventus by 21.9% during the 2nd quarter. Squarepoint Ops LLC now owns 269,267 shares of the company’s stock valued at $2,542,000 after acquiring an additional 48,414 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on BVS. Canaccord Genuity Group cut their target price on shares of Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Wall Street Zen lowered shares of Bioventus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 7th. Craig Hallum reiterated a “buy” rating and issued a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Weiss Ratings cut shares of Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Finally, Barrington Research set a $18.00 price objective on Bioventus in a research report on Thursday, August 6th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Bioventus has an average rating of “Moderate Buy” and a consensus price target of $16.60.
Check Out Our Latest Stock Report on BVS
Bioventus Stock Performance
NASDAQ BVS opened at $10.66 on Monday. Bioventus Inc. has a fifty-two week low of $6.47 and a fifty-two week high of $15.89. The stock has a market cap of $898.21 million, a price-to-earnings ratio of 13.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.66. The business has a fifty day moving average of $13.13 and a 200-day moving average of $11.04. The company has a quick ratio of 1.16, a current ratio of 1.68 and a debt-to-equity ratio of 0.72.
Bioventus (NASDAQ:BVS – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.17. The business had revenue of $142.44 million for the quarter. Bioventus had a return on equity of 26.31% and a net margin of 9.78%. As a group, analysts predict that Bioventus Inc. will post 0.78 earnings per share for the current fiscal year.
Bioventus Profile
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Further Reading
- Five stocks we like better than Bioventus
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NASDAQ:BVS – Free Report).
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
